Related Experiment Video

Updated: Aug 22, 2026

Ex Vivo Infection of Live Tissue with Oncolytic Viruses
12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

The discrete charm of oncolytic viruses: Toward the finish line

Pedro R Lowenstein1, Maria Luisa Varela2, Maria G Castro2

  • 1Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan Medical School, Ann Arbor, MI, USA.

Cancer Cell
|March 28, 2025
PubMed

Insights

Oncolytic viruses (OVs) show promise for treating various cancers. Advances in viral therapies, including gene-armed viruses and improved delivery methods, are enhancing their clinical efficacy against brain, lung, and other tumors.

Area of Science:

  • Oncology
  • Virology
  • Gene Therapy

Background:

  • Oncolytic viruses (OVs) are engineered viruses that selectively infect and kill cancer cells.
  • Current research focuses on optimizing OVs for treating diverse cancers, including brain, ovarian, lung, and pancreatic tumors.

Purpose of the Study:

  • To summarize recent advancements in oncolytic virus (OV) therapy for cancer treatment.
  • To discuss the mechanisms of action and strategies for enhancing OV efficacy.
  • To highlight challenges and promising clinical trial outcomes in OV-based cancer therapies.

Main Methods:

  • Review of recent scientific literature on oncolytic virus advancements.
  • Analysis of strategies for viral vector optimization, such as gene-arming and retargeting.
  • Discussion of delivery methods, including serial injections and systemic delivery (e.g., adeno-associated virus 9).

Main Results:

  • Replicating adenoviruses and herpes simplex virus 1 (HSV-1) armed with therapeutic transgenes show progress.
  • Systemic delivery via retargeting, exemplified by adeno-associated virus 9 (AAV9), is being explored.
  • Clinical trials indicate promising efficacy for OV-based cancer treatments.

Conclusions:

  • Oncolytic virus therapy is a rapidly advancing field with significant potential in oncology.
  • Continued research into viral engineering, delivery systems, and combination therapies is crucial for overcoming challenges.
  • OV treatments are demonstrating encouraging results in clinical trials for various solid tumors.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

Related Concept Videos

Lytic Cycle of Bacteriophages01:30

Lytic Cycle of Bacteriophages

Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the lytic replication...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
Rabies01:28

Rabies

Rabies is a lethal zoonotic disease caused by a single-stranded, negative-sense RNA virus of the Lyssavirus genus, within the family Rhabdoviridae. Its primary mode of transmission to humans is through bites or saliva-contaminated scratches from infected mammals such as dogs, bats, raccoons, or foxes. Transmission can also occur if infectious saliva contacts abraded skin or intact mucous membranes, including the conjunctiva.Viral Entry and Early ReplicationOnce introduced at the bite or scratch...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...